CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
CTS was recently notified that one of the tubes listed in the Sample Acceptability document...
After a thorough and comprehensive review of proposals received from suppliers of viral marker testi...
The Q & A document from the Reentry Changes Webinar hosted on 06/06/18 has been posted in the Wh...
TEMPE, Ariz. (Sept. 8, 2022) — Marion Lanteri, Ph.D., began this week as Creative Testing Solu...
We sincerely hope to see you at this year’s AABB Annual Meeting in San Antonio, TX on October ...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...